Vimarsana
Biggest News Aggregation in the World

Page 2 - Jeffrey Berkowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jeffrey Berkowitz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jeffrey Berkowitz Today - Breaking & Trending Today

Zealand Pharma convenes its Annual General Meeting 2022 - Vimarsana News

Zealand Pharma convenes its Annual General Meeting 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Amazon case study: how to hold online markets to account on fakes - Vimarsana News

Amazon case study: how to hold online markets to account on fakes

A recent case marks important progress in holding online marketplaces like Amazon accountable for counterfeit and infringing products made available through their channels, say Jeffrey Berkowitz, Danny Awdeh and Sonja Sahlsten of Finnegan

Novel Parkinson's disease therapy meets primary, secondary phase 3 endpoints - Vimarsana News

Novel Parkinson's disease therapy meets primary, secondary phase 3 endpoints

Pharma Two B, a company that uses reformulations and combinations of previously approved drugs to develop new therapies for neurological indications, announced its novel therapy for Parkinson’s disease met primary and secondary endpoints. The drug, P2B001, combines extended-release formulations of 0.6 mg of pramipexole and 0.75 mg of rasagiline in a fixed dose. It features both components

Source: healio.com
Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease - Vimarsana News

Pharma Two B Announces Positive Topline Results from its Pivotal Phase III Study of P2B001 in Early Parkinson's Disease

/PRNewswire/ -- Pharma Two B Ltd., a privately held company developing innovative therapeutics based on reformulation and combinations of previously approved...